You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes

References

• Mazur A. Why were “starvation diets” promoted for diabetes in the pre-insulin period? Nutr J. 2011;10(1):23. doi: 10.1186/1475-2891-10-23
   PubMedGoogle Scholar
• Vecchio I, Tornali C, Bragazzi NL, et al. The discovery of insulin: an important milestone in the history of medicine. Front Endocrinol. 2018;9:613. doi: 10.3389/fendo.2018.00613
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Juneja R, Beals JM, et al. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(5):733–755. doi: 10.1210/endrev/bnaa015
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Type 2 diabetes [updated 2023; cited 2022 Nov 25]. Available from: https://www.idf.org/aboutdiabetes/type-2-diabetes.html
   Google Scholar
• Clements JM, Rosca M, Cavallin C, et al. Type 2 diabetes and chronic conditions disparities in Medicare Beneficiaries in the state of Michigan. Am J Med Sci. 2020;359(4):218–225. doi: 10.1016/j.amjms.2020.01.013
   PubMed Web of Science ®Google Scholar
• Aktas G, Atak Tel BM, Tel R, et al. Treatment of type 2 diabetes patients with heart conditions. Expert Rev Endocrinol Metab. 2023;18(3):255–265. doi: 10.1080/17446651.2023.2204941
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–S178. doi: 10.2337/dc24-S009
   PubMedGoogle Scholar
• Andersen A, Knop FK, Vilsboll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81(9):1003–1030. doi: 10.1007/s40265-021-01499-w
   PubMed Web of Science ®Google Scholar
• Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315. doi: 10.3390/molecules27134315
   PubMed Web of Science ®Google Scholar
• Defronzo RBL. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. doi: 10.2337/db09-9028
   PubMed Web of Science ®Google Scholar
• Duckworth WC, Abraira C, Moritz TE, et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA diabetes trial. J Diabetes Complications. 2011;25(6):355–361. doi: 10.1016/j.jdiacomp.2011.10.003
   PubMed Web of Science ®Google Scholar
• Hemmer A, Maiter D, Buysschaert M, et al. Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients. Diabetes Metab Syndr. 2019;13(1):332–336. doi: 10.1016/j.dsx.2018.09.007
   PubMed Web of Science ®Google Scholar
• Weiss T, Yang L, Carr RD, et al. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022;10(1):e002517. doi: 10.1136/bmjdrc-2021-002517
   PubMed Web of Science ®Google Scholar
• Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–2345. doi: 10.2147/PPA.S277676
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412. doi: 10.2147/DMSO.S141235
   PubMed Web of Science ®Google Scholar
• Monami M, Liistro F, Scatena A, et al. Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018;20(5):1213–1222. doi: 10.1111/dom.13221
   PubMed Web of Science ®Google Scholar
• Frías JP, Maaske J, Suchower L, et al. Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy. Diabetes Obes Metab. 2022;24(1):61–71. doi: 10.1111/dom.14548
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack S, Pratley RE, Cherney DZI, et al. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021;9(1):e002484. doi: 10.1136/bmjdrc-2021-002484
   PubMed Web of Science ®Google Scholar
• Berard L, Antonishyn N, Arcudi K, et al. Insulin matters: a practical approach to basal insulin management in type 2 diabetes. Diabetes Ther. 2018;9(2):501–519. doi: 10.1007/s13300-018-0375-7
   PubMed Web of Science ®Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885. doi: 10.2337/diacare.26.3.881
   PubMed Web of Science ®Google Scholar
• Saisho Y. Obesity, type 2 diabetes and beta cell failure: an Asian perspective. J Mol Genet Med. 2014;S1:008. https://www.hilarispublisher.com/open-access/obesity-type-diabetes-and-beta-cell-failure-an-asian-perspective-1747-0862.S1-008.pdf
   Google Scholar
• Cersosimo E, Solis-Herrera C, Trautmann ME, et al. Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev. 2014;10(1):2–42. doi: 10.2174/1573399810666140214093600
   PubMedGoogle Scholar
• Lebovitz HE. Chapter 41: management of hyperglycemia with oral antihyperglycemic agents in type 2 diabetes. In: Kahn R, Weir GC King GL, et al. eds. Joslin’s diabetes mellitus, 14th ed., p. 687–710. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Garg SK, Rewers AH, Akturk HK Ever-increasing insulin-requiring patients globally. Diabetes Technol Ther. 2018;20(S2):S21–S24. doi: 10.1089/dia.2018.0101
   PubMedGoogle Scholar
• Lipska KJ, Yao X, Herrin J, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care. 2017;40(4):468–475. doi: 10.2337/dc16-0985
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee 13. Older adults: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S244–S257. doi: 10.2337/dc24-S013
   PubMedGoogle Scholar
• Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311(22):2315–2325. doi: 10.1001/jama.2014.5951
   PubMed Web of Science ®Google Scholar
• Sorli C, Heile MK. Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc. 2014;7:267–282. doi: 10.2147/JMDH.S64084
   PubMedGoogle Scholar
• Peyrot M, Rubin RR, Kruger DF, et al. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245. doi: 10.2337/dc09-1348
   PubMed Web of Science ®Google Scholar
• Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33(4):733–735. doi: 10.2337/dc09-1184
   PubMed Web of Science ®Google Scholar
• Cheng AYY, Patel DK, Reid TS, et al. Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther. 2019;36(5):1018–1030. doi: 10.1007/s12325-019-00925-6
   PubMed Web of Science ®Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–3417. doi: 10.2337/dc13-0331
   PubMed Web of Science ®Google Scholar
• Okemah J, Peng J, Quiñones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018;35(11):1735–1745. doi: 10.1007/s12325-018-0819-5
   PubMed Web of Science ®Google Scholar
• Patil R, Nasrin AN, Datta SS, et al. Popular misconceptions regarding the diabetes management: where should we focus our attention? J Clin Diagn Res. 2013;7(2):287–291. doi: 10.7860/JCDR/2013/4416.2749
   PubMedGoogle Scholar
• Brunton SA, White JR Jr., Renda SM. The role of basal insulin in type 2 diabetes management. J Fam Pract. 2005;Suppl:S1–8.
   PubMedGoogle Scholar
• Davis SN, Renda SM Psychological insulin resistance: overcoming barriers to starting insulin therapy. Diabetes Educ. 2006;32(Suppl 4):146S–152S. doi: 10.1177/0145721706289S226
   PubMedGoogle Scholar
• Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543–2545. doi: 10.2337/diacare.28.10.2543
   PubMed Web of Science ®Google Scholar
• Bin Rsheed A, Chenoweth I Barriers that practitioners face when initiating insulin therapy in general practice settings and how they can be overcome. World J Diabetes. 2017;8(1):28–39. doi: 10.4239/wjd.v8.i1.28
   PubMed Web of Science ®Google Scholar
• Hayes RP, Fitzgerald JT, Jacober SJ. Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. Int J Clin Pract. 2008;62(6):860–868. doi: 10.1111/j.1742-1241.2008.01742.x
   PubMed Web of Science ®Google Scholar
• Endocrine Society. Addressing insulin access and affordability: an Endocrine Society position statement. J Clin Endocrinol Metab. 2021;106(4):935–941. doi: 10.1210/clinem/dgaa817
   PubMed Web of Science ®Google Scholar
• Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. Report to Congress on the affordability of insulin 2022 Dec 16. [cited 2022 Dec 22]. Available from: https://aspe.hhs.gov/reports/insulin-affordability-rtc
   Google Scholar
• Wright EE Jr., Malone DC, Trujillo JM, et al. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin. J Manag Care Spec Pharm. 2022;28(6):592–603. doi: 10.18553/jmcp.2022.21436
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fleischmann H, Siegmund T, et al. Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update. Diabetes Ther. 2020;11(8):1645–1666. doi: 10.1007/s13300-020-00855-5
   PubMed Web of Science ®Google Scholar
• The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328. doi: 10.1056/NEJMoa1203858
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Fleischmann H, Landgraf W, et al. EARLY study: early basal insulin therapy under real-life conditions in type 2 diabetics. Diabetes, Stoffwechsel und Herz. 2012;21(2):91–97.
   Web of Science ®Google Scholar
• Hanefeld M, Fleischmann H, Schiffhorst G, et al. Predictors of response to early basal insulin treatment in patients with type 2 diabetes—the EARLY experience. Diabetes Technol Ther. 2014;16(4):241–246. doi: 10.1089/dia.2013.0246
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451. doi: 10.1007/s00125-005-0132-0
   PubMed Web of Science ®Google Scholar
• Balkau B, Home PD, Vincent M, et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014;37(8):2108–2113. doi: 10.2337/dc13-3010
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi: 10.2337/dci22-0034
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S111–S125. doi: 10.2337/dc24-S006
   PubMedGoogle Scholar
• Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract. 2022;28(10):923–1049. doi: 10.1016/j.eprac.2022.08.002
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med. 2018;168(8):569–576. doi: 10.7326/M17-0939
   PubMed Web of Science ®Google Scholar
• Ford ES, Cowie CC, Li C, et al. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011;3(1):67–73. doi: 10.1111/j.1753-0407.2010.00100.x
   PubMed Web of Science ®Google Scholar
• Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153–163. doi: 10.1093/clinchem/47.2.153
   PubMed Web of Science ®Google Scholar
• Nielsen LR, Ekbom P, Damm P, et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care. 2004;27(5):1200–1201. doi: 10.2337/diacare.27.5.1200
   PubMed Web of Science ®Google Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631–1640. doi: 10.2337/dc17-1600
   PubMed Web of Science ®Google Scholar
• Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028
   PubMed Web of Science ®Google Scholar
• Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400–405. doi: 10.2337/dc18-1444
   PubMed Web of Science ®Google Scholar
• Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1):e000991. doi: 10.1136/bmjdrc-2019-000991
   PubMedGoogle Scholar
• Lu J, Ma X, Shen Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther. 2020;22(2):72–78. doi: 10.1089/dia.2019.0251
   PubMed Web of Science ®Google Scholar
• Lu J, Wang C, Shen Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549–555. doi: 10.2337/dc20-1862
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Aroda VR, Billings LK, et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab. 2021;23(11):2572–2581. doi: 10.1111/dom.14504
   PubMed Web of Science ®Google Scholar
• Battelino T, Danne T, Edelman SV, et al. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: the head-to-head randomized controlled InRange trial. Diabetes Obes Metab. 2023;25(2):545–555. doi: 10.1111/dom.14898
   PubMed Web of Science ®Google Scholar
• Mehta R, Goldenberg R, Katselnik D, et al. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med. 2021;53(1):998–1010. 10.1080/07853890.2021.1925148
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hajos TR, Dain MP, et al. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27(6):1169–1174. doi: 10.1185/03007995.2011.573623
   PubMed Web of Science ®Google Scholar
• Khan H, Coyle F, Chowdhury T. Patients’ preference for subsequent therapy following secondary failure of metformin and sulphonylurea. Pract Diab Int. 2009;26(7):282–284. doi: 10.1002/pdi.1400
   Google Scholar
• DiBonaventura MD, Wagner JS, Girman CJ, et al. Multinational Internet-based survey of patient preference for newer oral or injectable type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397–406. doi: 10.2147/PPA.S14477
   PubMed Web of Science ®Google Scholar
• Polonsky W, Traylor L, Wei W, et al. More satisfied, but why? A pooled patient-level analysis of treatment satisfaction following the initiation of insulin glargine vs. comparators in insulin-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(3):255–261. doi: 10.1111/dom.12214
   PubMed Web of Science ®Google Scholar
• Mühlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Appl Health Econ Health Policy. 2013;11(3):163–180. doi: 10.1007/s40258-013-0023-3
   PubMedGoogle Scholar
• Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. Health Qual Life Outcomes. 2007;5(1):69. doi: 10.1186/1477-7525-5-69
   PubMedGoogle Scholar
• Lee AK, Warren B, Lee CJ, et al. The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care. 2018;41(1):104–111. doi: 10.2337/dc17-1669
   PubMed Web of Science ®Google Scholar
• Brown A, Guess N, Dornhorst A, et al. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab. 2017;19(12):1655–1668. doi: 10.1111/dom.13009
   PubMed Web of Science ®Google Scholar
• Trief PM, Cibula D, Rodriguez E, et al. Incorrect insulin administration: a problem that warrants attention. Clin Diabetes. 2016;34(1):25–33. doi: 10.2337/diaclin.34.1.25
   PubMedGoogle Scholar
• Kenny C, Hall G GLP-1 receptor agonist and basal insulin co-therapy in type 2 diabetes: clinical evidence and practicalities of use. Diabetes Prim Care 2015;17:80–85.
   Google Scholar
• Yang Y, Chen S, Pan H, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6944. doi: 10.1097/MD.0000000000006944
   PubMed Web of Science ®Google Scholar
• Dalal MR, Kazemi M, Ye F, et al. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: implications for treatment discontinuation and healthcare costs and utilization. Adv Ther. 2017;34(9):2083–2092. doi: 10.1007/s12325-017-0592-x
   PubMed Web of Science ®Google Scholar
• Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–1288. doi: 10.2337/diacare.28.6.1282
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 units·mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units·mL−1. Diabetes Care. 2015;38(4):637–643. doi: 10.2337/dc14-0006
   PubMed Web of Science ®Google Scholar
• Yang Y, Long C, Li T, et al. Insulin degludec versus insulin glargine on glycemic variability in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol. 2022;13:890090. doi: 10.3389/fendo.2022.890090
   PubMedGoogle Scholar
• Goldman J, Kapitza C, Pettus J, et al. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017;33(10):1821–1831. doi: 10.1080/03007995.2017.1335192
   PubMed Web of Science ®Google Scholar
• Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/mL once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36(9):2536–2542. doi: 10.2337/dc12-2329
   PubMed Web of Science ®Google Scholar
• Goldman J, Angueira-Serrano E, Gonzalez J, et al. Survey reveals patient and health care provider experiences and challenges with the use of high doses of basal insulin. Clin Diabetes. 2022;41(2):244–257. doi: 10.2337/cd22-0062
   Google Scholar
• Rosenstock J, Bajaj HS, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–2116. doi: 10.1056/NEJMoa2022474
   PubMed Web of Science ®Google Scholar
• Mathieu C, Asbjornsdottir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401(10392):1929–1940. doi: 10.1016/S0140-6736(23)00520-2
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023;11(6):414–425. doi: 10.1016/S2213-8587(23)00093-1
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Arsenault J, Fisher L, et al. Initiating insulin: how to help people with type 2 diabetes start and continue insulin successfully. Int J Clin Pract. 2017;71(8):e12973. doi: 10.1111/ijcp.12973
   PubMed Web of Science ®Google Scholar
• Krist AH, Tong ST, Aycock RA, et al. Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform. 2017;240:284–302.
   PubMedGoogle Scholar
• Saheb Kashaf M, McGill ET, Berger ZD Shared decision-making and outcomes in type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2017;100(12):2159–2171. doi: 10.1016/j.pec.2017.06.030
   PubMed Web of Science ®Google Scholar
• Coronado-Vázquez V, Canet-Fajas C, Delgado-Marroquín MT, et al. Interventions to facilitate shared decision-making using decision aids with patients in primary health care: a systematic review. Medicine (Baltimore). 2020;99(32):e21389. doi: 10.1097/MD.0000000000021389
   PubMed Web of Science ®Google Scholar
• Tamhane S, Rodriguez-Gutierrez R, Hargraves I, et al. Shared decision-making in diabetes care. Curr Diab Rep. 2015;15(12):112. doi: 10.1007/s11892-015-0688-0
   PubMed Web of Science ®Google Scholar
• Rariden C. Diabetes distress: assessment and management of the emotional aspect of diabetes mellitus. J Nurse Pract. 2019;15(9):653–656. doi: 10.1016/j.nurpra.2019.06.020
   Google Scholar
• American Diabetes Association Professional Practice Committee 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S77–S110. doi: 10.2337/dc24-S005
   PubMedGoogle Scholar
• Boels AM, Vos RC, Hermans TGT, et al. What determines treatment satisfaction of patients with type 2 diabetes on insulin therapy? An observational study in eight European countries. BMJ Open. 2017;7(7):e016180. doi: 10.1136/bmjopen-2017-016180
   PubMed Web of Science ®Google Scholar
• Gucciardi E, Xu C, Vitale M, et al. Evaluating the impact of onsite diabetes education teams in primary care on clinical outcomes. BMC Fam Pract. 2020;21(1):48. doi: 10.1186/s12875-020-01111-2
   PubMed Web of Science ®Google Scholar
• Duncan I, Ahmed T, Li QE, et al. Assessing the value of the diabetes educator. Diabetes Educ. 2011;37(5):638–657. doi: 10.1177/0145721711416256
   PubMed Web of Science ®Google Scholar
• James TL. Improving referrals to diabetes self-management education in medically underserved adults. Diabetes Spectr. 2021;34(1):20–26. doi: 10.2337/ds20-0001
   PubMedGoogle Scholar
• Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care. 2020;43(7):1636–1649. doi: 10.2337/dci20-0023
   PubMed Web of Science ®Google Scholar